Core Insights - The stock of Weigao Blood Products experienced a decline of 2.19% on November 11, with a trading volume of 263 million yuan. The net financing buy was negative at 527.39 million yuan, indicating a higher repayment than new purchases [1] Financing Overview - On November 11, Weigao Blood Products had a financing buy amount of 49.90 million yuan, with a total financing balance of 2.59 billion yuan, representing 15.85% of its market capitalization [1] - The company had no short selling activity on the same day, with both short selling and repayment amounts recorded as zero [1] Company Performance - As of September 30, the number of shareholders for Weigao Blood Products was 24,800, a decrease of 20.95% from the previous period. The average number of circulating shares per shareholder increased by 26.51% to 1,535 shares [2] - For the period from January to September 2025, the company reported a revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, marking a 7.92% increase year-on-year [2] Dividend Information - Since its A-share listing, Weigao Blood Products has distributed a total of 65.82 million yuan in dividends [3]
威高血净11月11日获融资买入4990.05万元，融资余额2.59亿元